1,822 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Acquired by Rehmann Capital Advisory Group

Rehmann Capital Advisory Group bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 1,822 shares of the biotechnology company's stock, valued at approximately $562,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Crossmark Global Holdings Inc. lifted its holdings in shares of United Therapeutics by 3.5% during the 1st quarter. Crossmark Global Holdings Inc. now owns 3,645 shares of the biotechnology company's stock worth $1,124,000 after acquiring an additional 123 shares during the last quarter. TD Private Client Wealth LLC raised its position in United Therapeutics by 29.8% during the first quarter. TD Private Client Wealth LLC now owns 4,762 shares of the biotechnology company's stock valued at $1,468,000 after purchasing an additional 1,092 shares in the last quarter. Envestnet Asset Management Inc. raised its position in United Therapeutics by 18.1% during the first quarter. Envestnet Asset Management Inc. now owns 71,909 shares of the biotechnology company's stock valued at $22,167,000 after purchasing an additional 11,029 shares in the last quarter. Concurrent Investment Advisors LLC bought a new stake in United Therapeutics during the first quarter worth about $227,000. Finally, World Investment Advisors boosted its holdings in shares of United Therapeutics by 79.2% in the 1st quarter. World Investment Advisors now owns 2,328 shares of the biotechnology company's stock worth $718,000 after purchasing an additional 1,029 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of several recent research reports. UBS Group decreased their price objective on United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a report on Monday, June 30th. Wells Fargo & Company reiterated an "equal weight" rating and set a $314.00 price target (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Cantor Fitzgerald initiated coverage on shares of United Therapeutics in a report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 price objective for the company. Wall Street Zen cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $383.08.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Raymond Dwek sold 3,000 shares of United Therapeutics stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $285.57, for a total transaction of $856,710.00. Following the sale, the director directly owned 1,750 shares of the company's stock, valued at approximately $499,747.50. The trade was a 63.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $279.96, for a total value of $3,079,560.00. Following the transaction, the executive vice president owned 36,781 shares in the company, valued at $10,297,208.76. This trade represents a 23.02% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 76,681 shares of company stock worth $22,813,739. 10.30% of the stock is owned by corporate insiders.

United Therapeutics Trading Down 0.1%

Shares of NASDAQ:UTHR opened at $300.16 on Friday. The company has a 50-day moving average price of $301.03 and a 200-day moving average price of $320.77. The company has a market cap of $13.54 billion, a price-to-earnings ratio of 11.98, a price-to-earnings-growth ratio of 6.58 and a beta of 0.53. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. United Therapeutics's quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.17 EPS. As a group, research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.